Journal article
Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome
L Photiou, C van der Weyden, C McCormack, H Miles Prince
Current Oncology Reports | SPRINGER | Published : 2018
Abstract
Purpose of Review: Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin lymphoma. Globally, the most common subtypes of CTCL are mycosis fungoides and Sézary syndrome. CTCL can confer significant morbidity and even mortality in advanced disease. Here we review the current and potential future treatments for advanced-stage CTCL. Recent findings: Heterogeneity of treatment choice has been demonstrated both in US and non-US centers. Systemic treatment choice is currently guided by prognostic features, incorporating stage, immunophenotypic and molecular findings, and patient-specific factors such as age and comorbidities. Randomized controlled studies are uncommon, and the literature i..
View full abstractGrants
Funding Acknowledgements
[ "Christopher McCormack has received compensation from Takeda Pharmaceuticals and MSD for participation on advisory boards.", "H. Miles Prince has received research funding through grants from Celgene, Takeda, Amgen, Novartis, Innate Pharma, and Eisai; has received honoraria from Celgene, Takeda, Amgen, Novartis, Innate Pharma, and Eisai; and has participated on advisory boards for Celgene, Takeda, Amgen, Novartis, Innate Pharma, and Eisai." ]